Literature DB >> 7902561

Neurochemical mechanism of action of anorectic drugs.

R Samanin1, S Garattini.   

Abstract

Studies with dexfenfluramine, an anorectic agent which releases 5-hydroxytryptamine (5-HT) from nerve terminals and inhibits its reuptake, have considerably increased our knowledge of the role of 5-HT in feeding control. 5-HT1B receptors mediate the satiating effect of dexfenfluramine, whereas the mechanism by which 5-HT uptake inhibitors such as fluoxetine and sertraline cause anorexia is not clear. Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly alpha 1-adrenoceptors. It has been suggested that beta- and alpha 1-adrenoceptors and D1 dopamine receptors are involved in their effect on food intake. The difficulties of extrapolation across species limit our knowledge of the mechanism of the anorectic action in humans. Significant advances in the treatment of feeding pathology will be linked to identifying new receptor types and subtypes for neurotransmitters and quantifying and modelling eating disorders such as binge-eating and food craving.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902561     DOI: 10.1111/j.1600-0773.1993.tb01537.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  13 in total

1.  D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell.

Authors:  B Kalyanasundar; Claudia I Perez; Alvaro Luna; Jessica Solorio; Mario G Moreno; David Elias; Sidney A Simon; Ranier Gutierrez
Journal:  J Neurophysiol       Date:  2015-05-13       Impact factor: 2.714

Review 2.  Pediatric obesity: etiology and treatment.

Authors:  Melissa K Crocker; Jack A Yanovski
Journal:  Pediatr Clin North Am       Date:  2011-10       Impact factor: 3.278

3.  Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity.

Authors:  David Pubill; Anna M Canudas; Mercè Pallàs; Antonio Camins; Jorge Camarasa; Elena Escubedo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-09       Impact factor: 3.000

4.  Effect of dexfenfluramine on the transcriptional activation of CRF and its type 1 receptor within the paraventricular nucleus of the rat hypothalamus.

Authors:  N Laflamme; S Bovetto; D Richard; S Rivest
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

5.  Hypothalamic neuropeptide Y (NPY) and the attenuation of hyperphagia in streptozotocin diabetic rats treated with dopamine D1/D2 agonists.

Authors:  Dong-Yih Kuo
Journal:  Br J Pharmacol       Date:  2006-05-15       Impact factor: 8.739

6.  Comparison of changes in the extracellular concentration of noradrenaline in rat frontal cortex induced by sibutramine or d-amphetamine: modulation by alpha2-adrenoceptors.

Authors:  K E Wortley; Z A Hughes; D J Heal; S C Stanford
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

7.  Regioselective alkylation of 1,3,4,5-tetrahydrobenzo[d]azepin-2-one and biological evaluation of the resulting alkylated products as potentially selective 5-HT₂c agonists.

Authors:  Navnit Prajapati; Rajani Giridhar; Anshuman Sinha; Ashish M Kanhed; Mange Ram Yadav
Journal:  Mol Divers       Date:  2015-04-28       Impact factor: 2.943

Review 8.  Pediatric obesity: etiology and treatment.

Authors:  Melissa K Crocker; Jack A Yanovski
Journal:  Endocrinol Metab Clin North Am       Date:  2009-09       Impact factor: 4.741

Review 9.  Pharmacotherapy for childhood obesity: present and future prospects.

Authors:  R Sherafat-Kazemzadeh; S Z Yanovski; J A Yanovski
Journal:  Int J Obes (Lond)       Date:  2012-08-28       Impact factor: 5.095

Review 10.  An evolving scientific basis for the prevention and treatment of pediatric obesity.

Authors:  P T Katzmarzyk; S Barlow; C Bouchard; P M Catalano; D S Hsia; T H Inge; C Lovelady; H Raynor; L M Redman; A E Staiano; D Spruijt-Metz; M E Symonds; M Vickers; D Wilfley; J A Yanovski
Journal:  Int J Obes (Lond)       Date:  2014-03-25       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.